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n a 1945 interview with The 
New York Times, Alexander 
Fleming, who won a Nobel 
Prize that year for his dis­
covery of pencillin, warned that 
misuse of the drug could result in 
selection for resistant bacteria. True 
to this prediction, resistance began 
to emerge within 10 years of the 
widescale introduction of penicillin. 
Indeed, although antibiotics have 
transformed the medical response 
to bacterial illness and rendered eas­
ily treatable many formerly deadly 
infections, the mishandling and 
misprescription of these drugs have 
transformed the bacterial popula­
tion such that many antibiotics have 
partially or entirely lost their effi­
cacy. The problem is severe enough 
that many experts believe the value 
of existing antibiotic therapies over 
the next 100 years is now uncertain. 
However, some also believe that 
with a proper response to the cur­
rent trend in antibiotic resistance, 
these drugs might once again serve 
their original function.
The Cure Is the Catalyst
Antibiotics fight bacteria through a 
variety of mechanisms. Penicillins, 
cephalosporins, carbapenems, and 
vancomycin kill bacteria by dam­
aging or inhibiting the synthesis of 
bacterial cell walls. Other antibiotics 
act through effects on bacterial DNA 
or RNA (quinolones and rifampin), 
proteins (aminoglycocides, chloram­
phenicol, tetracyclines, and macro­
lide antibiotics), or metabolism 
(trimethoprim and sulfonamides).  
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Bacteria are said to have “intrinsic resis­
tance” to an antibiotic when their normal 
characteristics render them immune to the 
antibiotic’s mechanism of effect. Intrinsic 
resistance is not affected by misuse of anti­
biotics. In fact, it is valuable in determin­
ing which antibiotic will be most effective 
against a certain microbe. For example, 
the outer membrane of gram­negative bac­
teria makes them relatively impermeable 
to hydrophobic compounds such as macro­
lide antibiotics, thus conferring intrinsic 
resistance to these drugs. Some bacteria 
can also use temporary strategies in which 
different genes are expressed or suppressed 
in order to enable survival in the presence 
of antibiotics, with expression patterns 
returning to normal once the threat posed 
by those particular drugs has passed. 
In contrast, bacteria may acquire resis­
tance to an antibiotic by taking on a new 
characteristic through gene mutation or 
the transfer of genetic material between 
bacteria. Acquired characteristics that can 
make bacteria resistant to an antibiotic 
include changes to the bacterial mem­
brane that prevent antibiotics from enter­
ing the cell. Bacteria may also use enzymes 
to break down antibiotics, or they may 
employ “efflux pumps” to remove the 
antibiotic entirely or reduce its concentra­
tion below effective levels. 
If a bacterium is able to perform more 
than one of these functions, it may be 
resistant to more than one type of anti­
biotic, resulting in multidrug resistance, 
according to P.M. Bennett, writing in the 
March 2008 issue of the British Journal 
of Pharmacology. At the same time, the 
possession of even a single form of efflux 
pump can lead to the export of—and 
protection against—more than one form 
of antibiotic, thus also conferring multi­
drug resistance, adds David McDowell, a 
professor of food studies at the University 
of Ulster. 
Mutations are relatively rare, occur­
ring in only 1 event per 107–1010 bac­
teria, according to a review by Michael 
R. Mulvey and Andrew E. Simor in the 
17 February 2009 issue of the Canadian 
Medical Association Journal. As an example, 
Mulvey and Simor pointed to isoniazid 
resistance among Mycobacterium tuberculo­
sis. “This form of resistance is not transfer­
able to other organisms,” they wrote. “The 
probability of multiple resistance mutations 
occurring in a single organism is equal to 
the product of their individual probabili­
ties. This is the rationale behind the use of 
combination therapy for the management 
of tuberculosis.”
Of greater concern are “promiscu­
ous” gene transfer systems that allow the 
sharing of genetic material between bac­
teria. One genetic transfer strategy is the 
exchange of conjugative plasmids. These 
circles of DNA, which are separate from 
the bacterial chromosome, can replicate 
independently and move between bacte­
ria carrying antibiotic resistance genes, 
thereby multiplying antibiotic resistance 
among successive generations within a 
bacterial colony. Bacteria may also acquire 
resistance genes through the spread of 
transposons or integrons, groups of linked 
genetic elements. 
In the July 2008 issue of the Journal 
of Bacteriology, Michael Gillings and col­
leagues wrote that class 1 integrons (the 
most extensively studied type of integron) 
now appear in 40–70% of gram­negative 
pathogens in clinical and agricultural sam­
ples. “The rapid spread of class 1 integrons 
through gram­negative and, more recently, 
into gram­positive species has been facili­
tated by their location on mobile DNA 
elements, such as plasmids and transpo­
sons, coupled with the selective advantage 
conferred by their associated antibiotic 
resistance genes,” they wrote. The authors 
noted about 10% of sequenced bacterial 
genomes carry integrons.
In some instances, resistance mecha­
nisms are induced by the presence of an 
antibiotic, says José L. Martínez, a micro­
biologist at the Spanish National Center 
of Biotechnology, but in most cases resis­
tance arises when susceptible bacteria are 
killed by the antibiotic and only those 
resistant few prevail and reproduce. In 
other words, antibiotics don’t cause resis­
tance. Instead, they select for resistant 
bacteria and increase the proportional 
prevalence.
Ironically, the impulse to scour equip­
ment and surfaces may sometimes end 
up worsening this situation, as M. Ann 
S. McMahon and colleagues pointed out 
in the January 2007 issue of Applied and 
Environmental Microbiology: “Detergents 
and solvents have been shown, among 
other compounds, to induce the [multiple 
antibiotic resistance] operon,” they wrote, 
describing food­preservation processes. 
“This operon regulates the expression of 
a large number of genes, including those 
coding for at least one broad­specificity 
efflux pump (the arcAB efflux pump), 
which are more strongly expressed under 
conditions of environmental stress. This 
suggests a direct linkage between environ­
mental stresses, such as those occurring 
in foods and the domestic environment, 
efflux pump expression, and the develop­
ment of antibiotic resistance.” The authors 
suggest that the increased use of sublethal 
bacteriostatic food preservation methods 
(as opposed to bactericidal methods) may 
be contributing to antibiotic resistance 
among food­related pathogens.
Case in Point
The problem of antibiotic resistance has 
become widely known in large part because 
of the emergence of methicillin­resistant 
Staphylococcus aureus (MRSA), an increas­
ingly common bacterial agent with fright­
ening consequences. Initially, most MRSA 
infections were contracted by hospital in­
patients suffering from other underlying 
conditions. Such infections were dubbed 
hospital­acquired MRSA (sometimes called 
healthcare­associated MRSA, and abbrevi­
ated in both cases as HA­MRSA). In 1974, 
2% of all S. aureus infections in the United 
States were HA­MRSA, according to the 
Centers for Disease Control and Preven­
tion. By 1995 this figure rose to 22% and 
by 2004 had reached 64%. More recently, 
MRSA infections have been reported 
among otherwise apparently healthy mem­
bers of the general population who have not 
undergone hospitalization or any invasive 
medical procedure within the past year. 
These infections are known as community­
acquired MRSA (CA­MRSA).
In the September 2008 issue of the 
Journal of Clinical Microbiology Fred C. 
Tenover and colleagues from the CDC 
reported on an extended study undertaken 
to characterize MRSA isolates collected 
as part of the National Health Examina­
tion and Nutrition Survey between 2001 
and 2004. A total of 19,412 nasal samples 
had been collected from noninstitutional­
ized individuals. Between 2001–2002 and 
2003–2004, the incidence of S. aureus in 
nasal samples decreased. However, during 
the same period, the prevalence of MRSA 
increased, reaching 1.5%. 
Moreover, colonization with MRSA 
can persist even after several years. In a 
study reported in the 1 April 2009 issue 
of Clinical Infectious Diseases, Ari Robicsek 
and colleagues examined 1,564 patients 
after positive MRSA identification and 
then retested them over a 4­year period. 
After one year, 48.8% of the patients were 
still colonized with MRSA. After four 
years, 21.2% were still colonized. The les­
son to be learned, according to the authors, 
is that “even in the fourth year after a 
positive clinical culture result, the risk of 
MRSA colonization does not subside to 
that of the general patient population.”
Risk factors for acquiring HA­MRSA 
include recent hospitalization, outpatient 
visits to the hospital, and nursing home 
admission.  CA­MRSA  infections  are 
also associated with antibiotic exposure, 
chronic illness, injection drug use, athletics   
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(particularly contact sports such as wres­
tling or those that involve handling a com­
munal object such as a volleyball), or close 
contact with someone who has one of these 
characteristics or exposures. Any sharing of 
equipment, clothing, or athletic facilities, 
or skin­to­skin contact, also increases the 
likelihood of acquiring MRSA. However, 
HA­MRSA and CA­MRSA have started 
to blend, with traditional risk factors pre­
dicting infection less accurately. 
Spotted in the Wild
In the 2001 report Hogging It! Estimates of 
Antimicrobial Abuse in Livestock, the Union 
of Concerned Scientists estimated that 
70% of all antibiotics used in the United 
States—more than 24 million pounds per 
year—is routinely put in the food and water 
of healthy livestock. Antibiotics are used in 
feed animals to not only control disease but 
also improve metabolism and reduce dietary 
requirements by stimulating the growth of 
microbes that produce vitamins and amino 
acids. In a review in the May 2007 issue of 
EHP, Amy R. Sapkota and colleagues wrote 
that the practice of using antibiotics at non­
therapeutic levels “has been shown to select 
for antibiotic resistance in both commensal 
and pathogenic bacteria in a) the animals 
themselves; b) subsequent animal­based 
food products; and c) water, air, and soil 
samples collected around large­scale animal 
feeding operations.” 
Veterinary antibiotics often are excret­
ed unchanged. In the April 2001 issue of 
Applied and Environmental Microbiology, 
for instance, J. C. Chee­Sanford and col­
leagues reported that up to 75% of tetra­
cycline administered to swine was excreted 
unaltered. The excreted drugs can persist 
in the environment, creating an opportu­
nity for resistance selection within exposed 
bacterial populations. 
Animal waste handling practices vary 
considerably between farms, but generally 
include “land application,” the spreading 
of waste on the soil surface as a fertilizer, 
which can result in contamination of soil 
and surface or ground water. Many con­
ventional farming operations also use waste 
lagoons, which provide an alternative route 
by which birds and insects can pick up 
antibiotic­resistant bacteria. 
A study by Jay P. Graham and col­
leagues in the 1 April 2009 issue of Science 
of the Total Environment reported that flies 
collected from the areas surrounding a 
poultry production facility demonstrated 
resistance consistent with the types of 
antibiotics being used there. Graham and 
colleagues suggested that “the carriage of 
antibiotic resistant enteric bacteria by flies 
in the poultry production environment 
increases the potential for human exposure 
to drug resistant bacteria.” 
And there is evidence that antibiotic­
resistant bacteria are traveling far. In the 
January 2008 issue of Emerging Infectious 
Diseases, Maria Sjöland and colleagues doc­
umented an unexpectedly high presence 
in Arctic wildlife of drug­resistant Escheri­
chia coli, which the authors speculate may 
have been transported by migratory birds.   
In another recent study, published in the 
March 2009 issue of FEMS Microbiology 
Ecology, Julie M. Rose and colleagues took 
472 bacterial isolates from vertebrates in 
coastal waters off the northeastern United 
States, including marine mammals, sharks, 
and birds, and found that 58% demon­
strated resistance to at least one antibiotic, 
whereas 43% were multidrug­resistant.
In 1996, the National Antibiotic Resis­
tance Monitoring System (NARMS) was 
formed as a joint effort of the Food and 
Drug Administration (FDA), the Centers 
for Disease Control and Prevention, and 
the U.S. Department of Agriculture to col­
lect data on bacteria present in humans 
and animals. In 2001, NARMS expanded 
to include sampling of retail meats col­
lected through random purchases from 
randomly selected groceries. NARMS first 
began sampling at locations in 6 states in 
2002, then increased to 8 states in 2003, 10 
in 2004, and 11 in 2008. The most recent 
NARMS report, 2006 NARMS Retail Meat 
Annual Report, presents some staggering 
numbers. In tests of chicken breast samples 
collected between 2002 and 2006, an aver­
age of 51.1% tested positive for Campylo­
bacter, 11.9% for Salmonella, 97.7% for E. 
coli, and 82.6% for Enterococcus. In many 
cases, these bacterial isolates also tested 
positive for resistance to one or more drugs.
One of the first studies to closely exam­
ine the occurrence of MRSA on U.S. farms 
looked at two swine production systems. As 
reported by Tara C. Smith and colleagues 
in the 23 January 2009 edition of PLoS 
ONE, one farm had extremely high levels of 
the ST398 strain of MRSA in both its ani­
mal population (49% overall, with 100% 
occurrence in animals aged 9–12 weeks) 
and its workers (64%). Yet, none of the 
animals or workers in the second farming 
system had MRSA, which may have to 
do with the source of the animals. Smith 
explains, “Because the farms got their ani­
mals from different sources, we’re guessing 
MRSA is moving via importation, bringing 
in pigs already colonized.”
Pharmaceutical factories, themselves, 
can be another source of antibiotics enter­
ing the environment. As Meghan Hessen­
auer, an environmental scientist at the U.S. 
Environmental Protection Agency, points 
out, guidelines for pharmaceutical manu­
facturing wastes are geared toward the dis­
charge of chemicals used in the process of 
manufacturing rather than active pharma­
ceutical ingredients. This, she says, means 
“there is no regulation and no limits on 
antibiotics themselves.” 
Other Environmental Inputs
There are best management practices in 
place to prevent such industrial releases, 
says Hessenauer. Nevertheless, drugs are 
still making their way out of at least some 
manufacturing plants. In one survey of a 
wastewater treatment plant that received 
effluent from a penicillin G production 
facility, published online 18 February 2009 
ahead of print in Environmental Microbiology, 
Dong Li and colleagues demonstrated that, 
compared with upstream samples, effluent 
and downstream samples showed signifi­
cantly high levels of resistance for almost 
all the antibiotics they tested for.
At the household level, recent stud­
ies have found a correlation between the 
disposal of antibiotics and the emergence 
of resistance. In research performed by 
Dean A. Seehusen and John Edwards and 
described in the November–December 
2006 issue of the Journal of the American 
Board of Family Medicine, more than half 
the patients surveyed had flushed unused 
or expired pharmaceuticals down the toilet. 
Only 22.9% reported returning unused 
medication to a pharmacy, and still fewer 
had received information from a health 
care provider about proper medication 
disposal. In the December 2005 issue of 
EHP, Jonathan Bound and Nikolaos Voul­
voulis reported similar numbers from a 
U.K. study in which only 21.8% of survey 
respondents returned unused medications 
to their pharmacies. 
As with farm animals, antibiotics may 
be excreted by humans in their original 
active form. Up to 80% of amoxicillin, 
for example, may be excreted unaltered 
in urine. In the October 2000 issue of 
Antimicrobial Agents and Chemotherapy, 
for instance, Niels Høiby and colleagues 
reported that excretion of ceftriaxone and 
ceftazidime in sweat “may have contrib­
uted significantly to the present worldwide 
selection for and spread of MRSA.” When 
excreted antibiotics do make their way 
to sewage treatment plants, they aren’t 
necessarily removed from the water, nor 
are antibiotic­resistance bacteria. In the 
December 2005 issue of The Journal of 
General and Applied Microbiology Xavier 
Vilanova and Anicet R. Blanch reported 
finding vancomycin­ and erythromycin­
resistant bacteria in liquid and dried sludge 
from a treatment plant. Focus | The Landscape of Antibiotic Resistance
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In one study, more than half 
of survey respondents reported 
flushing unused antibiotics 
down the toilet.
HOMES
PHARMACEUTICAL 
FACTORIES
Current regulations address 
discharges of chemicals used 
to produce antibiotics but 
not antibiotics themselves 
that end up in plant effluent.
FARMS
Application of farm waste 
to lands can put antibiotics 
and resistant bacteria in soil 
and water.
Studies since the 1970s have 
shown hospital effluent to 
contain higher levels of antibiotic-
resistant enteric bacteria than 
waste from other sources.
HOSPITALS
How Antibiotics Enter 
the Environment
ANTIBIOTICS 
in the
Environment
How Resistance Works 
1 Efflux pumps are transport proteins that 
remove an antibiotic entirely or reduce 
its concentration below effective levels. 
They may be specific to one compound, 
or they may work on a range of  
dissimilar compounds.
2 Antibiotics can be inactivated by  
enzymes that (a) modify or (b) degrade 
them. These enzymes typically are  
specific to a particular antibiotic or class 
of antibiotics.
3 Molecular binding sites can be modi-
fied, for instance, through mutation of 
ribosomal RNA or other key elements.
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(Right) Intrinsic antibiotic 
resistance is a fact of  
bacterium life. Antibiotics 
do not induce resistance. 
Instead, they select 
for those few resistant 
bacteria in any given 
population, which then 
reproduce and create 
an increasingly resistant 
population through 
successive generations. 
How Resistance Spreads
(Below) It is relatively rare 
that bacteria acquire resistance 
through spontaneous mutation. 
For more often, they acquire 
resistance by exchanging con-
jugative plasmids, circular units 
of DNA (resistance genes are 
indicated in red). Bacteria may 
also transfer resistance genes 
packaged in viruses or acquire 
segments of DNA released from 
dead cells.
Antibiotic-sensitive Dead
Drug Antibiotic-resistant
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viral delivery
Transfer of free 
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Researchers are still evaluating how dis­
infectants and antibacterial products such 
as handsoap may impact antibiotic resis­
tance. In the April 2003 issue of Clinical 
Microbiology Reviews, Peter Gilbert and 
Andrew J. McBain wrote, “While the regu­
lar application and use of antimicrobial 
handwashing products have been noted to 
bring about a change in skin flora, this has 
not been associated with fluctuations in 
resistance.” The following year, the Board 
of the International Scientific Forum on 
Home Hygiene issued a consensus state­
ment declaring “there is no evidence that 
biocide use has been a significant factor to 
date in the development of antibiotic resis­
tance in clinical practice—antibiotic mis­
use is the most significant causative factor.” 
The board noted, however, that “it is 
important to ensure that biocides are used 
responsibly as part of a good hygiene rou­
tine in the domestic setting in order to 
avoid the possibility of any impact on anti­
microbial resistance in the future.” Indeed, 
the same holds true for community­scale 
hygiene. In the June 2004 issue of Eco­
toxicology and Environmental Safety, Richa 
Shrivastava reported that suboptimal chlo­
rination of water taken from India’s River 
Gomti appeared to select for multidrug­
resistant Pseudomonas aeruginosa, an oppor­
tunistic pathogen.
On the Trail of the Resistance  
Footprint
David Patrick and James Hutchinson sug­
gested in the 17 February 2009 issue of the 
Canadian Medical Association Journal that a 
“resistance footprint” can help identify and 
measure antibiotic hazards. That is, every­
one connected with antibiotics through 
production, prescription, consumption, and 
disposal should consider their own poten­
tial contributions to the problem (their 
“footprint”) as well as their role in prevent­
ing the spread of antibiotic resistance. Says 
Patrick, “The price for use of a specific 
course of antibiotics isn’t necessarily suf­
fered by the person who takes them. In 
addition to potential therapeutic benefits 
from using antibiotics, there is a contribu­
tion to the selective pressure to resistance 
that affects other people.”
Effective stewardship programs that 
promote the “resistance footprint” concept 
must acknowledge and address financial 
incentives for antibiotic use among farmers, 
on whom the burden of maintaining their 
herds rests and for whom financial con­
straints are often a great concern. Patrick 
says, “When I speak with food producers 
about pressure to get rid of antibiotics, they 
say a complication in North America is that 
we have a common food market between 
the United States and Canada, so if one 
side moves and perceives an economic 
disadvantage, they worry about putting 
themselves out of business. We need joint 
Canadian and U.S. support of agricultural 
regulations.” If farmers could be shown the 
longer­term economic benefits of steward­
ship and “footprint” management, he adds, 
they might be more inclined to adopt strat­
egies that would limit use of antibiotics and 
reduce resistance.
So far, the majority of efforts to pre­
vent and reduce antibiotic resistance have 
occurred in the field of health care, with 
infectious disease practitioners and research­
ers leading a call to reduce unnecessary 
use of antibiotics and adopt other steward­
ship strategies. Hospitals have implemented 
stewardship programs that bring interested 
parties together to identify problem drugs, 
retrieve historical patient data, and review 
standing formulary policies in order to 
develop strategies to manage antimicrobial 
use and monitor resistance patterns. 
In 2007, the Infectious Diseases Society 
of America and the Society for Health­
care Epidemiology of America issued its 
“Guidelines for Developing an Institutional 
Program to Enhance Antimicrobial Stew­
ardship.” Some of these guidelines are well 
validated, such as optimizing antimicro­
bial dosing based on the individual patient, 
infectious agent, and site of infection. 
Others—such as substituting one antibiotic 
for another—have not yet been validated. 
Research to identify new antibiotics 
for which resistance has not yet developed 
also is ongoing. However, the high cost of 
new drug development, combined with the 
more stringent approval criteria adopted 
in recent years by the FDA, is prohibitive 
for many larger pharmaceutical compa­
nies. The FDA’s desire to prevent further 
resistance from emerging also means that a 
“new compound that makes it through reg­
ulatory approval will be put on a restricted 
list to be used only when other antibiotics 
have failed, thereby limiting its market,” 
wrote Julian Davies in volume 8, number 7 
(2007) of EMBO Reports. 
New drug development, says Stu­
art Levy, a professor of molecular biology 
and microbiology at Tufts University, may 
therefore end up in the hands of academia 
or smaller pharmaceutical companies. “The 
smaller companies are able to focus on a 
single organism or a single product, devot­
ing their energies and people to that singu­
lar focus,” he explains. “In large companies, 
particularly when you get to the level of 
animal studies, you have to wait in a queue 
in order to do your analysis.”
Meanwhile, reining in antibiotic use is 
easier said than done. With cephalosporin 
resistance occurring at alarming rates, the 
FDA on 3 July 2008 proposed a withdraw­
al of extra­label uses of this class of anti­
biotics in food­producing animals, mean­
ing farmers could no longer legally use 
these drugs for anything other than FDA­
approved uses listed on the label. How­
ever, on 25 November 2008, the agency 
withdrew the proposal “in order for FDA 
to fully consider the comments” received 
from groups such as the American Associa­
tion of Swine Veterinarians (AASV), which 
argued the ban was based on unsubstanti­
ated data. A news item in the January/
February 2009 issue of the AASV’s Journal 
of Swine Health and Production notes that 
“It seems . . . that given the fact that anti­
microbials affect all susceptible bacteria in 
the animal being treated, whether or not 
that bacteria is on the approved label, the 
more rational approach would be to use an 
approved product for the [animal] species 
being treated rather than a product labeled 
for a different [animal] species.” 
The presence of antibiotic resistance 
genes in surface water, groundwater, at sew­
age treatment plants, landfills, and a variety 
of agricultural and aquacultural locations 
means pollution of the environment has not 
only been chemical. And although limiting 
antibiotic use and creating programs that 
control dissemination of antibiotics can pre­
vent the problem of resistance from worsen­
ing and may even reduce the problem, it’s 
unclear whether resistant strains will neces­
sarily be replaced by susceptible ones, says 
Martínez. Moreover, says Gillings, “The 
natural disappearance of antibiotic­resistant 
strains is very slow—much slower than the 
rate of their appearance.” 
Still, some studies suggest that reduc­
ing use of antibiotics at the level of an 
individual medical practice is associated 
with reduced local antibiotic resistance. 
For instance, in the 1 October 2007 issue 
of The British Journal of General Practice, 
Chris C. Butler and colleagues showed that 
antibiotic resistance could be effectively 
reduced within an observable period. Specif­
ically, they observed an overall reduction of 
resistance to ampicillin (1% per year) and 
trimethoprim (0.6% per year) in practices 
that reduced their prescriptions of those 
drugs. Although modest, these findings 
may suggest the possibility of a sustained 
decline in resistance, wrote Butler and col­
leagues, thus “preserving the international 
reservoir of antibiotic susceptibility.” 
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